Skip to main content

SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism

Tumor Biology volume 36, pages 4133–4141 (2015)Cite this article

Abstract

Sterol regulatory element-binding protein 1 (SREBP1) is a known transcription factor of lipogenic genes, which plays important roles in regulating de novo lipogenesis. Accumulating evidences indicate SREBP1 is involved in tumorigenesis, yet its role in pancreatic cancer remains unclear. Here, we explored the expression characteristic and function of SREBP1 in pancreatic cancer. Analysis of 60 patients with pancreatic ducat cancer showed that SREBP1 level was significantly higher in pancreatic cancer than that in adjacent normal tissues. High expression of SREBP1 predicted poor prognosis in patients with pancreatic cancer. Multivariate analysis revealed that SREBP1 was an independent factor affecting overall survival. SREBP1 silencing resulted in proliferation inhibition and induction of apoptosis in pancreatic cancer cells. Mechanistically, lipogenic genes (acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), and stearoyl-CoA desaturase-1 (SCD1)) and de novo lipogenesis were promoted by SREBP1. Inhibition of lipogenic genes through specific inhibitors ablated SREBP1-mediated growth regulation. Furthermore, depletion of SREBP1 could suppress lipid metabolism and tumor growth in vivo. Our results indicate that SREBP1 had important role in tumor progression and appears to be a novel prognostic marker for pancreatic cancer.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.

    Article  PubMed  Google Scholar 

  2. Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control. 2008;15(4):280–7.

    PubMed  Google Scholar 

  3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.

    CAS  Article  PubMed  Google Scholar 

  4. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308. doi:10.1016/j.ccr.2012.02.014.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10(4):267–77. doi:10.1038/nrc2817.

    CAS  Article  PubMed  Google Scholar 

  6. Sun Y, Zhao X, Zhou Y, Hu Y. miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncol Rep. 2012;28(4):1346–52. doi:10.3892/or.2012.1958.

    CAS  PubMed  Google Scholar 

  7. Sun Y, Zhao X, Luo M, Zhou Y, Ren W, Wu K, et al. The pro-apoptotic role of the regulatory feedback loop between miR-124 and PKM1/HNF4alpha in colorectal cancer cells. Int J Mol Sci. 2014;15(3):4318–32. doi:10.3390/ijms15034318.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–77. doi:10.1038/nrc2222.

    CAS  Article  PubMed  Google Scholar 

  9. Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2380–5. doi:10.1158/1055-9965.EPI-09-0144.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. Zhao X, Feng D, Wang Q, Abdulla A, Xie XJ, Zhou J, et al. Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. J Clin Invest. 2012;122(7):2417–27. doi:10.1172/JCI61462.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012;148(1–2):244–58. doi:10.1016/j.cell.2011.12.017.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. Yang F, Vought BW, Satterlee JS, Walker AK, Jim Sun ZY, Watts JL, et al. An ARC/mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature. 2006;442(7103):700–4. doi:10.1038/nature04942.

    CAS  Article  PubMed  Google Scholar 

  13. Walker AK, Jacobs RL, Watts JL, Rottiers V, Jiang K, Finnegan DM, et al. A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell. 2011;147(4):840–52. doi:10.1016/j.cell.2011.09.045.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–31. doi:10.1172/JCI15593.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8(3):224–36. doi:10.1016/j.cmet.2008.07.007.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Guo D, Bell EH, Chakravarti A. Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncol. 2013;2(3):289–99. doi:10.2217/cns.13.20.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. Huang WC, Li X, Liu J, Lin J, Chung LW. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res. 2012;10(1):133–42. doi:10.1158/1541-7786.MCR-11-0206.

    CAS  Article  PubMed  Google Scholar 

  18. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004;64(6):2212–21.

    CAS  Article  PubMed  Google Scholar 

  19. Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, et al. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle. 2012;11(12):2348–58. doi:10.4161/cc.20811.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. Sun Y, Zhao X, Yao Y, Qi X, Yuan Y, Hu Y. Connexin 43 interacts with Bax to regulate apoptosis of pancreatic cancer through a gap junction-independent pathway. Int J Oncol. 2012;41(3):941–8. doi:10.3892/ijo.2012.1524.

    CAS  PubMed  Google Scholar 

  21. Zhao X, Xiaoli, Zong H, Abdulla A, Yang ES, Ji JY, et al. Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity. Diabetes. 2014. doi:10.2337/db13-0835.

    Google Scholar 

  22. Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013;1(1):3. doi:10.1186/2049-3002-1-3.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 2009;100(9):1369–72. doi:10.1038/sj.bjc.6605007.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De novo lipogenesis in health and disease. Metabolism. 2014;63(7):895–902. doi:10.1016/j.metabol.2014.04.003.

    CAS  Article  PubMed  Google Scholar 

  25. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140(3):1071–83. doi:10.1053/j.gastro.2010.12.006.

    CAS  Article  PubMed  Google Scholar 

  26. Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol. 2009;50(1):100–10. doi:10.1016/j.jhep.2008.07.036.

    CAS  Article  PubMed  Google Scholar 

  27. Israel M, Schwartz L. The metabolic advantage of tumor cells. Mol Cancer. 2011;10:70. doi:10.1186/1476-4598-10-70.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014;20(9):2279–303. doi:10.3748/wjg.v20.i9.2279.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This study was supported by research grants from National Natural Science Foundation of China (Nos. 81201532 and 81372195), Young Teacher Scientific Capability Promotion Project of Fudan University (No. 20520133490), Shanghai Pujiang Program (No. 13PJ1406000), Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (No. 1410000157),Science and Technology Commission of Shanghai Municipality (No. 134119a5600) and Shanghai Municipal Commission of Health and Family Planning (XYQ2013109).

Conflicts of interest

The authors declare no conflict of interest.

Author information

Author notes

    Affiliations

    1. Department of Geriatrics, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, China

      Yan Sun, Man Luo, Guilin Chang, Weiying Ren, Kefen Wu, Xi Li, Jiping Shen & Yu Hu

    2. Department of Thoracic Surgery, Sixth People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China

      Weiwei He

    3. Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China

      Yuhong Zhou

    4. Department of Nuclear Medicine, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China

      Xiaoping Zhao

    Authors
    1. Yan Sun
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Weiwei He
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Man Luo
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Yuhong Zhou
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Guilin Chang
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Weiying Ren
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Kefen Wu
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Xi Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Jiping Shen
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Xiaoping Zhao
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Yu Hu
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Xiaoping Zhao or Yu Hu.

    Additional information

    Yan Sun and Weiwei He contributed equally to this work.

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Sun, Y., He, W., Luo, M. et al. SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism. Tumor Biol. 36, 4133–4141 (2015). https://doi.org/10.1007/s13277-015-3047-5

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-3047-5

    Keywords

    • SREBP1
    • Pancreatic cancer
    • Apoptosis
    • Prognosis
    • Lipid metabolism